Anticoagulation safety monitoring

Baseline checks, follow-up monitoring, and escalation triggers for outpatient anticoagulation care.

Last reviewed February 7, 2026

Red flags

Active major bleeding, hemodynamic instability, or signs of intracranial hemorrhage.
Severe renal deterioration with uncertainty about safe continued dosing.
Recurrent falls, major drug interactions, or inability to maintain safe medication use.

Confirm indication, treatment phase, and intended treatment duration before starting or changing therapy.
Review bleeding history, renal function trajectory, liver function concerns, and adherence reliability.
Reconcile interacting medications (including over-the-counter NSAIDs and herbal supplements).

Capture baseline CBC, renal function, and clinically indicated liver tests before major therapy changes.
Document weight, age, and relevant comorbidities that affect dosing safety.
Use Cockcroft-Gault creatinine clearance for DOAC dose thresholds, not the laboratory-reported eGFR; verify the agent and indication-specific regimen.
Verify anticoagulation education readiness and follow-up access.

Choose regimen and dose using current guideline-aligned indication-specific pathways.
Provide counseling on missed doses, bleeding warning symptoms, and when to seek urgent care.
Use the same monitoring framework at every follow-up to reduce omission risk.
Check CBC and renal function at least every 6-12 months during stable long-term DOAC use, earlier if risk or health changes. INR/aPTT are not reliable routine DOAC intensity tests; warfarin requires INR monitoring.

Complex comorbidity, recurrent bleeding risk, or recurrent thrombosis despite treatment.
Persistent uncertainty around indication, duration, or agent choice.
Need for specialist-guided anticoagulation strategy beyond primary-care scope.

Something out of date or unclear? Suggest an update. Leave out any patient details.